Analyst Reviews on Overselling: Novavax, Inc. (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX) share price plunged -0.34% or -0.003 points to reach at $0.827 during previous trading session. The stock’s price fluctuated within the range of $0.82 – $0.87 during previous trading session. A total of 5.76M shares exchanged hands, whereas the company’s average trading volume stands at 6.11M shares. Novavax, Inc. (NASDAQ:NVAX) has a market capitalization of $211.10M and most recently 271.95M outstanding shares have been calculated.

In terms of market analysis and trading signals, RSI moving above the horizontal 30 reference level is viewed as a bullish indicator, while the RSI moving below the horizontal 70 reference level is seen to be a bearish indicator. Movements above 70 are interpreted as indicating overbought conditions; conversely, movements under 30 reflect oversold conditions.

Relative strength index (RSI-14) for Novavax, Inc. (NASDAQ:NVAX) is at 19.57.

According to sentiments of 6 analysts the mean estimates of short term price target for the company’s stock is marked at $3.58. The most optimistic analyst sees the stock reaching $12 while the most conventional predicts the target price at $3.58.

The consensus mean EPS for the current quarter is at $-0.17 derived from a total of 7 estimates. According to analysts minimum EPS for the current quarter is expected at $-0.19 and can go high up to $-0.13. However a year ago during same quarter Novavax, Inc. (NASDAQ:NVAX) reported $-0.29 EPS.

For the upcoming quarter, initial predictions are anticipating that the company will post earnings of $-0.16 per share according to consensus of 7analysts.

According to sentiments of 6 analysts the company is expected to report revenues of $6.17M for the current quarter. Bearish revenue estimates established at $4M while the bullish revenue forecast has been figured out at $9M.

In terms of Buy/Sell recommendations, analysts have a consensus rating of 2.62 on the shares of Novavax, Inc. (NASDAQ:NVAX). Out of rating recommendations 1 have given the stock a Buy while 1 recommend the stock as Outperform. 6 have given the stock a Hold rating, 0 as Underperform and 0 as Sell.

On technical side, moving averages may help to distinguish direction of tendencies, and they might also be used to set levels of sustenance and resistance. Novavax, Inc. (NASDAQ:NVAX)’s distance from 20 day simple moving average is -24.47% whereas its distance from 50 day simple moving average is -36.08% along with -72.48% distance from 200 day simple moving average.

An important factor to consider when evaluating a stock’s current and future value are the 52 week price high and low levels. Novavax, Inc. (NASDAQ:NVAX) shares were trading -90.26% below from the 52-week high mark of $8.49 and +13.25% above from the 52-week bottom of $0.73. The stock hit its 52-week high price on 09/15/16 and 52-week low price on 04/06/17.

When we have a peek on stock’s historical trends we come to know that, the stock has slipped –7.11% in the past one week and plunged -37.37% during previous one month drive, the stock went down -41.78% during past quarter. In the last six months the stock’s performance fell -45.97% while yearly performance of the company fell -84.46%.The company’s year to date (YTD) performance is at -34.39%.

While taking a glance at financials, we can look at a number of key indicators. Novavax, Inc. (NASDAQ:NVAX) has a Return on Assets (ROA) of -56.80%. The company currently has a Return on Equity (ROE) of -329.60%. Average true range (ATR-14) of the company sets at 0.08, along with its weekly and monthly volatility of 7.12%, 9.10% respectively. Beta value of the stock stands at 2.13.

The company’s quick ratio for most recent quarter is 4.30 along with current ratio for most recent quarter of 4.30.

Featured Stock: Novavax, Inc. (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX) share price plunged -0.50% or -0.004 points to reach at $0.896 during previous trading session. The stock’s price fluctuated within the range of $0.81 – $0.94 during previous trading session. A total of 9.38M shares exchanged hands, whereas the company’s average trading volume stands at 6.50M shares. Novavax, Inc. (NASDAQ:NVAX) has a market capitalization of $242.53M and most recently 271.95M outstanding shares have been calculated.

In terms of market analysis and trading signals, RSI moving above the horizontal 30 reference level is viewed as a bullish indicator, while the RSI moving below the horizontal 70 reference level is seen to be a bearish indicator. Movements above 70 are interpreted as indicating overbought conditions; conversely, movements under 30 reflect oversold conditions.

Relative strength index (RSI-14) for Novavax, Inc. (NASDAQ:NVAX) is at 22.71.

According to sentiments of 6 analysts the mean estimates of short term price target for the company’s stock is marked at $3.58. The most optimistic analyst sees the stock reaching $12.00 while the most conventional predicts the target price at $1.50.

The consensus means EPS for the current quarter is at -$0.12 derived from a total of 7 estimates. According to analysts minimum EPS for the current quarter is expected at -$0.19 and can go high up to -$0.13. However a year ago during same quarter Novavax, Inc. (NASDAQ:NVAX) reported -$0.29 EPS.

For the upcoming quarter, initial predictions are anticipating that the company will post earnings of -$0.16 per share according to consensus of 7 analysts.

According to sentiments of 6 analysts the company is expected to report revenues of $6.17M for the current quarter. Bearish revenue estimates established at $4M while the bullish revenue forecast has been figured out at $9M.

In terms of Buy/Sell recommendations, analysts have a consensus rating of 2.62 on the shares of Novavax, Inc. (NASDAQ:NVAX). Out of rating recommendations 1 have given the stock a Buy while 1 recommend the stock as Outperform. 6 have given the stock a Hold rating, 0 as Underperform and 0 as Sell.

On technical side, moving averages may help to distinguish direction of tendencies, and they might also be used to set levels of sustenance and resistance. Novavax, Inc. (NASDAQ:NVAX) distance from 20 day simple moving average is -29.19% whereas its distance from 50 day simple moving average is -33.47% along with -71.98% distance from 200 day simple moving average.

An important factor to consider when evaluating a stock’s current and future value are the 52 week price high and low levels. Novavax, Inc. (NASDAQ:NVAX) shares were trading -89.40% below from the 52-week high mark of $8.49 and 23.29% above from the 52-week bottom of $0.73. The stock hit its 52-week high price on 09/15/16, and 52-week low price on  04/06/17.

When we have a peek on stock’s historical trends we come to know that, the stock has slipped -29.696% in the past one week and plunged -38.36% during previous one month drive, the stock went down -34.31% during past quarter. In the last six months the stock’s performance fell -52.13% while yearly performance of the company fell -83.67%. The company’s year to date (YTD) performance is at -28.57%.

While taking a glance at financials, we can look at a number of key indicators. Novavax, Inc. (NASDAQ:NVAX) has a Return on Assets (ROA) of -56.80%. The company currently has a Return on Equity (ROE) of -329.60%. Average true range (ATR-14) of the company sets at 0.09, along with its weekly and monthly volatility of 17.84%, 7.36% respectively. Beta value of the stock stands at 2.08.

Noticeable Earnings: Novavax, Inc. (NASDAQ:NVAX)

Shares of Novavax, Inc. (NASDAQ:NVAX) jumped 18.12% to reach at $1.63 during previous trading session. The company has experienced volume of 9,247,253 shares while on average the company has a capacity of trading 6.86M share.

Novavax, Inc. (NASDAQ:NVAX) on February 28, 2017 announced its financial results for the fourth quarter and twelve months ended December 31, 2016.

Novavax reported a net loss of $57.1 million, or $0.21 per share, for the fourth quarter of 2016, compared to a net loss of $78.8 million, or $0.29 per share, for the fourth quarter of 2015. For the twelve months ended December 31, 2016, the net loss was $280.0 million, or $1.03 per share, compared to a net loss of $156.9 million, or $0.60 per share, for the same period in 2015.

Novavax revenue in the fourth quarter of 2016 decreased 8% to $5.4 million, compared to $5.9 million for the same period in 2015. Revenue for the full year 2016 decreased 58% to $15.4 million, compared to $36.3 million in 2015.  The decrease in revenue under the HHS BARDA contract in 2016 of approximately $31 million relative to 2015 accounts for the decrease. The lower HHS BARDA revenue is the result of a lower level of activity, primarily resulting from the natural expiration of the BARDA contract, as compared to the same period in 2015.

Research and development expenses decreased 33% to $51.1 million in the fourth quarter of 2016, compared to $75.9 million for the same period in 2015. For the full year 2016, research and development expenses increased 46% to $237.9 million, compared to $162.6 million in 2015.  The increase in research and development expenses for the full year 2016 was primarily due to increased costs associated with the clinical trials and development activities of our RSV F Vaccine and higher employee-related costs, including non-cash stock-based compensation.

Novavax, Inc. (NASDAQ:NVAX) holds the market capitalization of $522.23M along with 271.25M outstanding shares. During the last trade, stock’s minimum price has been reached out at $1.40 while the maximum trading price moved at $1.63. Currently the stock price is moving -80.80% off from the highest level of twelve months and +40.52% above from twelve months low. Novavax, Inc. (NASDAQ:NVAX) marked 52-week highest price level of $8.49 on 09/15/16 and 52-week lowest price level of $1.16 on 09/16/16. For the stock, price target value has been calculated at $3.29 based on calls of 7 experts. Stock’s minimum price target estimates has been figured out at $1.50 while the maximum price target forecast is established at $12.00.

As of current trade, Novavax, Inc. (NASDAQ:NVAX) has shown weekly upbeat performance of 7.95%. Its six months performance indicated a bearish movement while its yearly performance reflected a negative trend of -65.39%. Year-to-date (YTD) performance of the stock illustrate upbeat trend of 29.37%. Shares of Novavax, Inc. (NASDAQ:NVAX) currently have an ABR of 2.67, derived from a total of 6 opinions. The company’s price sits 19.31% above from its 50-day moving average of $1.39 and -57.89% below from the stock’s 200-day moving average of $2.52. The company has Relative Strength Index (RSI 14) of 66.21 along with Average True Range (ATR 14) of 0.10. Its weekly and monthly volatility is 8.82%, 6.98% respectively. The company’s beta value is at 1.86.

Novavax, Inc. (NASDAQ:NVAX)’s price to sales ratio for trailing twelve months is 27.98 and price to book ratio for most recent quarter is 9.06, whereas price to cash per share for the most recent quarter is 1.47. Novavax, Inc. (NASDAQ:NVAX)’s quick ratio for most recent quarter is 4.70 along with current ratio for most recent quarter of 4.70. Total debt to equity ratio of the company for most recent quarter is 6.35 whereas long term debt to equity ratio for most recent quarter is 6.35. Novavax, Inc. (NASDAQ:NVAX) has a Return on Assets of -61.50%. The company currently has a Return on Equity of -189.10% and Return on Investment of -53.60%.

Price Target Estimates Under Analyst’s Radar: Novavax, Inc. (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX) plunged -3.70% during previous trade, a total of 21.36M shares exchanged hands compared with its average trading volume of 6.18M shares whereas its relative volume is 3.18. The stock has a market capitalization of $482.74M along with 271.25M outstanding shares. Stock’s intraday price range hit the peak level of $1.78 and touched the lowest level of $1.48.

Most recently Novavax, Inc. (NASDAQ:NVAX)’s price target was revised on 11/14/16 and according to 7 analysts stock’s price will reach at $3.29 during 52 weeks with standard deviation of 6.39. Stock’s minimum price target estimates has been figured out at $1.50 while the maximum price target forecast is established at $12, if we look at the price target with an optimistic approach it has upside potential of 669% from its latest closing price of $1.56

Historically, if we look at price target revisions, one week ago Novavax, Inc. (NASDAQ:NVAX)’s price target was revised on 11/14/16 by the analysts, however the bullish price estimates of the stock set at $14.15 while the bearish estimates kept at $1.50 over the next one year. Stock’s 52-week target was retained at $6.13, the estimates indicates a standard deviation of 6.39.

While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 2.67. ABR value is precisely based on brokerage recommendations, where out of 6 brokerage recommendations 1 rate Novavax, Inc. (NASDAQ:NVAX) stock a Strong Buy, 0 rate the stocks of the company a Buy, 5 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Most recently on 9/16/16 the stock of Novavax, Inc. (NASDAQ:NVAX) downgraded by Citigroup from Buy to Neutral. However previously on 9/16/16 it was downgraded by Wedbush from Outperform to Neutral. A research note issued on 9/16/16 the stock was downgraded by Ladenburg Thalmann from Buy to Neutral.

Novavax, Inc. (NASDAQ:NVAX) performance over the past one year plunged -67.90% whereas its year to date (YTD) performance indicated a bullish trend of 23.81%. During the last six months the stock slipped -78.80%. Quarterly performance of the company shows optimistic momentum of 14.71% while its last one month trend is positive with 9.86%. Stock’s weekly performance expressed up trend of 18.18%.

The company’s price sits 14.84% above from its 50-day moving average of $1.36 and -60.70% below from the stock’s 200-day moving average which is $2.87. Novavax, Inc. (NASDAQ:NVAX)’s shares are currently trading -81.63% away from the 52-week high price of $8.49 and +34.48% far from the 52-week low price of $1.16.

According to consensus agreement of 9 analysts Novavax, Inc. (NASDAQ:NVAX) will report earnings per share of $-0.23 in their quarterly report and it is expected to announce the company’s results on 3/6/17. For the current quarter the company has high EPS estimates of $-0.21 in contradiction of low EPS estimates of $-0.24. However a year ago for the same quarter the company has reported $-0.29 EPS. Current year EPS projections for Novavax, Inc. (NASDAQ:NVAX) set at $-1.05 according to the sentiments of 9 analysts, while its lowest earnings estimates are $-1.06 and highest earnings estimates are $-1.03.

According to 8 analysts, Novavax, Inc. (NASDAQ:NVAX)’s revenue estimates for the current quarter are $5.45M meanwhile the company has high revenue estimates of $9M in contradiction of low revenue estimates of $3.5M. For the current year the company’s revenue estimates are $15.44M compared to low analyst estimates of $13.45M and high estimates of $18.9M according to the projection of 8 analysts.

Price Reaction History Under Analysts Radar: Novavax, Inc. (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX) plunged -0.77% during previous trade, a total of 5.98M shares exchanged hands compared with its average trading volume of 7.42M shares whereas its relative volume is 0.64. The stock has a market capitalization of $344.61M along with 271.25M outstanding shares. Stock’s intraday price range hit the peak level of $1.32 and touched the lowest level of $1.26.

Most recently Novavax, Inc. (NASDAQ:NVAX)’s price target was revised on 11/14/16 and according to 7 analysts stock’s price will reach at $3.29 during 52 weeks with standard deviation of 6.39. Stock’s minimum price target estimates has been figured out at $1.50 while the maximum price target forecast is established at $12, if we look at the price target with an optimistic approach it has upside potential of 830% from its latest closing price of $1.29.

Historically, if we look at price target revisions, one week ago Novavax, Inc. (NASDAQ:NVAX)’s price target was revised on 11/14/16 by the analysts, however the bullish price estimates of the stock set at $14.15 while the bearish estimates kept at $1.50 over the next one year. Stock’s 52-week target was retained at $6.13, the estimates indicates a standard deviation of 6.39.

While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 2.67. ABR value is precisely based on brokerage recommendations, where out of 6 brokerage recommendations 1 rate Novavax, Inc. (NASDAQ:NVAX) stock a Strong Buy, 0 rate the stocks of the company a Buy, 5 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Most recently on 9/16/16 the stock of Novavax, Inc. (NASDAQ:NVAX) downgraded by Citigroup from Buy to Neutral. However previously on 9/16/16 it was downgraded by Wedbush from Outperform to Neutral. A research note issued on 9/16/16 the stock was downgraded by Ladenburg Thalmann from Buy to Neutral.

Novavax, Inc. (NASDAQ:NVAX) performance over the past one year plunged -84.55% whereas its year to date (YTD) performance indicated a bearish trend of -84.62%. During the last six months the stock slipped -82.26%. Quarterly performance of the company shows declining momentum of -37.38% while its last one month trend is positive with 1.57%. Stock’s weekly performance expressed down trend of -6.52%.

The company’s price sits -7.27% below from its 50-day moving average of $1.33 and -72.13% below from the stock’s 200-day moving average which is $4.27. Novavax, Inc. (NASDAQ:NVAX)’s shares are currently trading -85.24% away from the 52-week high price of $8.74 and +11.21% far from the 52-week low price of $1.16.

According to consensus agreement of 9 analysts Novavax, Inc. (NASDAQ:NVAX) will report earnings per share of $-0.23 in their quarterly report and it is expected to announce the company’s results on 3/6/17. For the current quarter the company has high EPS estimates of $-0.21 in contradiction of low EPS estimates of $-0.24. However a year ago for the same quarter the company has reported $-0.29 EPS. Current year EPS projections for Novavax, Inc. (NASDAQ:NVAX) set at $-1.05 according to the sentiments of 9 analysts, while its lowest earnings estimates are $-1.06 and highest earnings estimates are $-1.03.

According to 8 analysts, Novavax, Inc. (NASDAQ:NVAX)’s revenue estimates for the current quarter are $5.45M meanwhile the company has high revenue estimates of $9M in contradiction of low revenue estimates of $3.5M. For the current year the company’s revenue estimates are $15.72M compared to low analyst estimates of $13.67M and high estimates of $18.9M according to the projection of 7 analysts.

Momentum Stock: Novavax, Inc. (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX) share price soared 2.10% or +0.03 points to reach at $1.46 during previous trading session. The stock’s price fluctuated within the range of $1.41 – $1.54 during previous trading session. A total of 14,541,200 shares exchanged hands, whereas the company’s average trading volume stands at 19.62M shares. Novavax, Inc. (NASDAQ:NVAX) has a market capitalization of $404.33M and most recently 271.25M outstanding shares have been calculated.

In terms of market analysis and trading signals, RSI moving above the horizontal 30 reference level is viewed as a bullish indicator, while the RSI moving below the horizontal 70 reference level is seen to be a bearish indicator. Movements above 70 are interpreted as indicating overbought conditions; conversely, movements under 30 reflect oversold conditions.

Relative strength index (RSI-14) for Novavax, Inc. (NASDAQ:NVAX) is at 55.09.

According to sentiments of 6 analysts the mean estimates of short term price target for the company’s stock is marked at $3.50. The most optimistic analyst sees the stock reaching $12.00 while the most conventional predicts the target price at $1.50.

The consensus mean EPS for the current quarter is at $-0.23 derived from a total of 8 estimates. According to analysts minimum EPS for the current quarter is expected at $-0.24 and can go high up to $-0.21. However a year ago during same quarter Novavax, Inc. (NASDAQ:NVAX) reported $-0.29 EPS.

For the upcoming quarter, initial predictions are anticipating that the company will post earnings of $-0.17 per share according to consensus of 5 analysts.

According to sentiments of 7 analysts the company is expected to report revenues of $5.25M for the current quarter. Bearish revenue estimates established at $3.5M while the bullish revenue forecast has been figured out at $9M.

In terms of Buy/Sell recommendations, analysts have a consensus rating of 2.62 on the shares of Novavax, Inc. (NASDAQ:NVAX). Out of rating recommendations 1 have given the stock a Buy while 1 recommend the stock as Outperform. 6 have given the stock a Hold rating, 0 as Underperform and 0 as Sell.

On technical side, moving averages may help to distinguish direction of tendencies, and they might also be used to set levels of sustenance and resistance. Novavax, Inc. (NASDAQ:NVAX)’s distance from 20 day simple moving average is 11.28% whereas its distance from 50 day simple moving average is -3.55% along with -69.93% distance from 200 day simple moving average.

Important factors to consider when evaluating a stock’s current and future value are the 52 week price high and low levels. Novavax, Inc. (NASDAQ:NVAX) shares were trading -83.69% below from the 52-week high mark of $8.95 and +25.86% above from the 52-week bottom of $1.16. The stock hit its 52-week high price on 12/17/15, and 52-week low price on 09/16/16.

When we have a peek on stock’s historical trends we come to know that, the stock has slipped 17.74% in the past one week and plunged -14.12% during previous one month drive, the stock went down -82.15% during past quarter. In the last six months the stock’s performance fell -77.01% while yearly performance of the company fell -82.30%. The company’s year to date (YTD) performance is at -82.60%.

While taking a glance at financials, we can look at a number of key indicators. Novavax, Inc. (NASDAQ:NVAX) has a Return on Assets (ROA) of -61.50%. The company currently has a Return on Equity (ROE) of -189.10% and a Return on Investment (ROI) of -53.60%. Average true range (ATR-14) of the company sets at 0.11, along with its weekly and monthly volatility of 10.04%, 7.11% respectively. Beta value of the stock stands at 1.84.

The company’s quick ratio for most recent quarter is 4.70 along with current ratio for most recent quarter of 4.70. Total debt to equity ratio of the company for most recent quarter is 6.35 whereas long term debt to equity ratio for most recent quarter is 6.35.

Stock under Review: Novavax, Inc. (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX) share price plunged -17.5% or -0.30 points to reach at $1.40 during previous trading session. The stock’s price fluctuated within the range of $1.32 – $1.53 during previous trading session. A total of 22.85M shares exchanged hands, whereas the company’s average trading volume stands at 10.76M shares. Novavax, Inc. (NASDAQ:NVAX) has a market capitalization of $445.12M and most recently 271.24M outstanding shares have been calculated.

In terms of market analysis and trading signals, RSI moving above the horizontal 30 reference level is viewed as a bullish indicator, while the RSI moving below the horizontal 70 reference level is seen to be a bearish indicator. Movements above 70 are interpreted as indicating overbought conditions; conversely, movements under 30 reflect oversold conditions.

Relative strength index (RSI-14) for Novavax, Inc. (NASDAQ:NVAX) is at 28.54.

According to sentiments of 7 analysts the mean estimates of short term price target for the company’s stock is marked at $5.02. The most optimistic analyst sees the stock reaching $14.15 while the most conventional predicts the target price at $1.

The consensus mean EPS for the current quarter is at $-0.26 derived from a total of 8 estimates. According to analysts minimum EPS for the current quarter is expected at $-0.29 and can go high up to $-0.23. However a year ago during same quarter Novavax, Inc. (NASDAQ:NVAX) reported $-0.12 EPS.

For the upcoming quarter, initial predictions are anticipating that the company will post earnings of $-0.25 per share according to consensus of 8 analysts.

According to sentiments of 7 analysts the company is expected to report revenues of $4.02M for the current quarter. Bearish revenue estimates established at $2M while the bullish revenue forecast has been figured out at $5M.

In terms of Buy/Sell recommendations, analysts have a consensus rating of 2.62 on the shares of Novavax, Inc. (NASDAQ:NVAX). Out of rating recommendations 1 have given the stock a Buy while 1 recommend the stock as Outperform. 6 have given the stock a Hold rating, 0 as Underperform and 0 as Sell.

On technical side, moving averages may help to distinguish direction of tendencies, and they might also be used to set levels of sustenance and resistance. Novavax, Inc. (NASDAQ:NVAX)’s distance from 20 day simple moving average is -7.50% whereas its distance from 50 day simple moving average is -53.30% along with -73.11% distance from 200 day simple moving average.

An important factor to consider when evaluating a stock’s current and future value are the 52 week price high and low levels. Novavax, Inc. (NASDAQ:NVAX) shares were trading -84.83% below from the 52-week high mark of $9.23 and +20.69% above from the 52-week bottom of $1.16. The stock hit its 52-week high price on 12/2/15 and 52-week low price on 9/16/16.

When we have a peek on stock’s historical trends we come to know that, the stock has climbed 14.75% in the past one week and plunged -13.58% during previous one month drive, the stock went down -80.11% during past quarter. In the last six months the stock’s performance fell -68.25% while yearly performance of the company fell -79.38%.The company’s year to date (YTD) performance is at -83.31%.

While taking a glance at financials, we can look at a number of key indicators. Novavax, Inc. (NASDAQ:NVAX) has a Return on Assets (ROA) of -56.30%. The company currently has a Return on Equity (ROE) of -112.40% and a Return on Investment (ROI) of -53.60%. Average true range (ATR-14) of the company sets at 0.16, along with its weekly and monthly volatility of 13.63%, 8.79% respectively. Beta value of the stock stands at 1.98.

The company’s quick ratio for most recent quarter is 5.10 along with current ratio for most recent quarter of 5.10. Total debt to equity ratio of the company for most recent quarter is 2.87 whereas long term debt to equity ratio for most recent quarter is 2.87.

Stock Earnings Roundup: Novavax, Inc. (NASDAQ:NVAX)

Shares of Novavax, Inc. (NASDAQ:NVAX) jumped 17.24% to reach at $1.70 during previous trading session. The company has experienced volume of 15,826,000 shares while on average the company has a capacity of trading 18.31M share.

Novavax, Inc. (NASDAQ:NVAX) on November 10, 2016 announced its financial results for the third quarter and nine months ended September 30, 2016.

Novavax reported a net loss of $66.3 million, or $0.24 per share, for the third quarter of 2016, compared to a net loss of $33.1 million, or $0.12 per share, for the third quarter of 2015. For the nine months ended September 30, 2016, the net loss was $222.9 million, or $0.82 per share, compared to a net loss of $78.1 million, or $0.30 per share, for the same period in 2015.

Novavax revenue in the third quarter of 2016 decreased 50% to $3.2 million, compared to $6.5 million for the same period in 2015. Lower revenue under the HHS BARDA contract of $6.2 million is the primary driver of this decrease. The lower HHS BARDA revenue is the result of a lower level of activity in the three months ended September 30, 2016, primarily resulting from the natural expiration of the HHS BARDA contract, as compared to the same period in 2015.

Research and development expenses increased 73% to $53.0 million in the third quarter of 2016, compared to $30.7 million for the same period in 2015. The increase in research and development expenses was primarily due to increased costs associated with the clinical trials and development activities of its RSV F Vaccine and higher employee-related costs, including non-cash stock-based compensation.

Novavax, Inc. (NASDAQ:NVAX) holds the market capitalization of $454.75M along with 271.19M outstanding shares. During the last trade, stock’s minimum price has been reached out at $1.44 while the maximum trading price moved at $1.70. Currently the stock price is moving -81.58% off from the highest level of twelve months and +46.55% above from twelve months low. Novavax, Inc. (NASDAQ:NVAX) marked 52-week highest price level of $9.23 on 12/02/15 and 52-week lowest price level of $1.16 on 09/16/16. For the stock, price target value has been calculated at $5.02 based on calls of 7 experts. Stock’s minimum price target estimates has been figured out at $1.00 while the maximum price target forecast is established at $14.15.

As of current trade, Novavax, Inc. (NASDAQ:NVAX) has shown weekly upbeat performance of 26.87%. Its six months performance indicated a bearish movement while its yearly performance reflected a positive negative trend of -75.78%. Year-to-date (YTD) performance of the stock illustrate downbeat trend of -79.74%. Shares of Novavax, Inc. (NASDAQ:NVAX) currently have an ABR of 2.67, derived from a total of 6 opinions. The company’s price sits -45.21% below from its 50-day moving average of $1.74 and -67.46% below from the stock’s 200-day moving average of $5.27. The company has Relative Strength Index (RSI 14) of 34.69 along with Average True Range (ATR 14) of 0.14. Its weekly and monthly volatility is 12.74%, 8.53% respectively. The company’s beta value is at 1.98.

Novavax, Inc. (NASDAQ:NVAX)’s price to sales ratio for trailing twelve months is 26.51 and price to book ratio for most recent quarter is 4.15, whereas price to cash per share for the most recent quarter is 1.38. Novavax, Inc. (NASDAQ:NVAX)’s quick ratio for most recent quarter is 5.10 along with current ratio for most recent quarter of 5.10. Total debt to equity ratio of the company for most recent quarter is 2.87 whereas long term debt to equity ratio for most recent quarter is 2.87. Novavax, Inc. (NASDAQ:NVAX) has a Return on Assets of -56.30%. The company currently has a Return on Equity of -112.40% and Return on Investment of -53.60%.

Stock on Analysts Radar: Novavax, Inc. (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX) soared 18.85% during previous trade, a total of 15.60M shares exchanged hands compared with its average trading volume of 15.56M shares whereas its relative volume is 0.88. The stock has a market capitalization of $392.22M along with 271.19M outstanding shares. Stock’s intraday price range hit the peak level of $1.52 and touched the lowest level of $1.25.

Most recently Novavax, Inc. (NASDAQ:NVAX)’s price target was revised on 9/29/16 and according to 7 analysts stock’s price will reach at $5.02 during 52 weeks with standard deviation of 6.40. Stock’s minimum price target estimates has been figured out at $1 while the maximum price target forecast is established at $14.15, if we look at the price target with an optimistic approach it has upside potential of 876% from its latest closing price of $1.45.

Historically, if we look at price target revisions, one week ago Novavax, Inc. (NASDAQ:NVAX)’s price target was revised on 9/20/16 by the analysts, however the bullish price estimates of the stock set at $14.15 while the bearish estimates kept at $1 over the next one year. Stock’s 52-week target was retained at $6.13, the estimates indicates a standard deviation of 6.40.

While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 2.67. ABR value is precisely based on brokerage recommendations, where out of 6 brokerage recommendations 1 rate Novavax, Inc. (NASDAQ:NVAX) stock a Strong Buy, 0 rate the stocks of the company a Buy, 5 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Most recently on 9/16/16 the stock of Novavax, Inc. (NASDAQ:NVAX) downgraded by Citigroup from Buy to Neutral. However previously on 9/16/16 it was downgraded by Wedbush from Outperform to Neutral. A research note issued on 9/16/16 the stock was downgraded by Ladenburg Thalmann from Buy to Neutral.

Novavax, Inc. (NASDAQ:NVAX) performance over the past one year plunged -81.36% whereas its year to date (YTD) performance indicated a bearish trend of -82.72%. During the last six months the stock slipped -69.73%. Quarterly performance of the company shows declining momentum of -80.72% while its last one month trend is negative with -22.87%. Stock’s weekly performance expressed up trend of 0.69%.

The company’s price sits -57.86% below from its 50-day moving average of $1.73 and -72.60% below from the stock’s 200-day moving average which is $5.35. Novavax, Inc. (NASDAQ:NVAX)’s shares are currently trading -84.29% away from the 52-week high price of $9.23 and +25% far from the 52-week low price of $1.16.

According to consensus agreement of 8 analysts Novavax, Inc. (NASDAQ:NVAX) will report earnings per share of $-0.26 in their quarterly report and it is expected to announce the company’s results on 11/9/16 Before Market Open. For the current quarter the company has high EPS estimates of $-0.23 in contradiction of low EPS estimates of $-0.29. However a year ago for the same quarter the company has reported $-0.12 EPS. Current year EPS projections for Novavax, Inc. (NASDAQ:NVAX) set at $-1.09 according to the sentiments of 8 analysts, while its lowest earnings estimates are $-1.16 and highest earnings estimates are $-1.02.

According to 7 analysts, Novavax, Inc. (NASDAQ:NVAX)’s revenue estimates for the current quarter are $40.2M meanwhile the company has high revenue estimates of $5M in contradiction of low revenue estimates of $2M. For the current year the company’s revenue estimates are $16.61M compared to low analyst estimates of $11.2M and high estimates of $22.2M according to the projection of 7 analysts.

Investor’s Watch List: Novavax, Inc. (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX) share price plunged -1.92% or -0.03 points to reach at $1.53 during previous trading session. The stock’s price fluctuated within the range of $1.50 – $1.58 during previous trading session. A total of 7.96M shares exchanged hands, whereas the company’s average trading volume stands at 32.50M shares. Novavax, Inc. (NASDAQ:NVAX) has a market capitalization of $397.10M and most recently 271.19M outstanding shares have been calculated.

In terms of market analysis and trading signals, RSI moving above the horizontal 30 reference level is viewed as a bullish indicator, while the RSI moving below the horizontal 70 reference level is seen to be a bearish indicator. Movements above 70 are interpreted as indicating overbought conditions; conversely, movements under 30 reflect oversold conditions.

Relative strength index (RSI-14) for Novavax, Inc. (NASDAQ:NVAX) is at 24.67.

According to sentiments of 7 analysts the mean estimates of short term price target for the company’s stock is marked at $5.02. The most optimistic analyst sees the stock reaching $14.15 while the most conventional predicts the target price at $1.

The consensus mean EPS for the current quarter is at $-0.26 derived from a total of 8 estimates. According to analysts minimum EPS for the current quarter is expected at $-0.29 and can go high up to $-0.23. However a year ago during same quarter Novavax, Inc. (NASDAQ:NVAX) reported $-0.12 EPS.

For the upcoming quarter, initial predictions are anticipating that the company will post earnings of $-0.25 per share according to consensus of 8 analysts.

According to sentiments of 7 analysts the company is expected to report revenues of $4.02M for the current quarter. Bearish revenue estimates established at $2M while the bullish revenue forecast has been figured out at $5M.

In terms of Buy/Sell recommendations, analysts have a consensus rating of 2.62 on the shares of Novavax, Inc. (NASDAQ:NVAX). Out of rating recommendations 1 have given the stock a Buy while 1 recommend the stock as Outperform. 6 have given the stock a Hold rating, 0 as Underperform and 0 as Sell.

On technical side, moving averages may help to distinguish direction of tendencies, and they might also be used to set levels of sustenance and resistance. Novavax, Inc. (NASDAQ:NVAX)’s distance from 20 day simple moving average is -20.52% whereas its distance from 50 day simple moving average is -69.71% along with -73.01% distance from 200 day simple moving average.

An important factor to consider when evaluating a stock’s current and future value are the 52 week price high and low levels. Novavax, Inc. (NASDAQ:NVAX) shares were trading -83.42% below from the 52-week high mark of $9.23 and +31.90% above from the 52-week bottom of $1.16. The stock hit its 52-week high price on 12/2/15, and 52-week low price on 9/16/16.

When we have a peek on stock’s historical trends we come to know that, the stock has slipped -18.62% in the past one week and soared 18.60% during previous one month drive, the stock went down -78.93% during past quarter. In the last six months the stock’s performance fell -71.24% while yearly performance of the company fell -80.08%.The company’s year to date (YTD) performance is at -81.76%.

While taking a glance at financials, we can look at a number of key indicators. Novavax, Inc. (NASDAQ:NVAX) has a Return on Assets (ROA) of -56.30%. The company currently has a Return on Equity (ROE) of -112.40% and a Return on Investment (ROI) of -53.60%. Average true range (ATR-14) of the company sets at 0.39, along with its weekly and monthly volatility of 7.63%, 9.95% respectively. Beta value of the stock stands at 1.93.

The company’s quick ratio for most recent quarter is 5.10 along with current ratio for most recent quarter of 5.10. Total debt to equity ratio of the company for most recent quarter is 2.87 whereas long term debt to equity ratio for most recent quarter is 2.87.